Business Wire

ETA

19.5.2023 18:55:34 CEST | Business Wire | Press release

Share
Egypt: A Family-Friendly Exotic Destination

If you are planning a family holiday, look no further than Egypt. The country is renowned for its all-inclusive hotels and resorts that cater to the needs of families with children. These resorts offer entertainment programs and excursions suitable for all age groups. Museums and cultural sights also offer family-friendly activities. Furthermore, Egypt's warm temperatures and dry climate throughout the year make it an ideal destination for holidays all year round, with sandy beaches and shallow water that are sure to excite children.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005234/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Family Holiday in Egypt (Photo: Business Wire)

What Makes a Holiday Family-Friendly?

A holiday is meant to be a time for relaxation, escaping everyday life and enjoying oneself. However, this can be challenging when traveling with children. Egypt's all-inclusive hotels and resorts provide stress-free options for families with children. The resorts offer animation programs for children of different ages, with pools featuring water slides and children's pools. In addition, multilingual caretakers are available to look after children when parents want to pursue their own plans undisturbed for an afternoon or evening. This allows parents to relax and enjoy their holiday with peace of mind.

Activities for the whole Family

There are many activities that families can enjoy together in Egypt. Clubs and resorts offer a range of sports activities, including mini golf, beach football, and volleyball. For those interested in water activities like diving, snorkelling, or kite surfing, there are beginner courses as well as special children's courses available.

In the cities itself, families can find a variety of activities like water parks, amusement parks, safari tours, and aquariums. Additionally, museums can be a great way to make history exciting for children, with the Egyptian Museum in Cairo offering guided tours specifically designed for kids. Outside of the cities, families can have adventures like desert tours in buggies or riding on camels. Compared to similar activities in Europe, leisure activities in Egypt are much more affordable, allowing families to experience more together or take some time for themselves to relax.

"Nile Trips and Abu Simbel"

Aswan, the southernmost city in Egypt, is located directly on the Nile, making it an excellent starting point for interesting and varied tours. Visitors can take Nile trips to the temples of Kom Ombo and even further north to Luxor. Close to the city lies Lake Nasser, at the southern end of which stands the spectacular temple complex of Abu Simbel. The four 20-metre-high statues of Pharaoh Ramses II at the main entrance of the temple are an incomparable sight and rightly rank among the most popular sights in the country.

Aswan itself is also full of treasures to discover, such as the Agha Khan Mausoleum on the west bank of the Nile, or the archaeological Nubian Museum that highlights the history of the Nubian population, who make up a large part of Aswan's inhabitants. The city also includes numerous islands in the Nile, such as Elephantine Island, or Kitchener Island to the north, where the city's botanical garden can be found.

Background information on the Egyptian Tourism Authority
The Egyptian Tourism Authority (ETA) was established in 1981 to boost international tourism by highlighting Egypt's long history and traditional civilization and promoting the country and its many tourist attractions. ETA's mission also includes promoting domestic tourism, raising awareness of tourism throughout the country, and strengthening the connection between Egyptians and their heritage.

The ETA's focus is on the one hand on the diversity of attractions and destinations within Egypt, and on the other hand on developing marketing strategies and programs to promote tourism, as well as providing technical and marketing support. It also organizes and sponsors tourism, sports, and social and cultural events throughout the country. The ETA Board of Directors is chaired by the Minister of Tourism.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005234/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye